Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other 1

Conditions

Breast Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoking Cessation 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1Obesity 1Neoplasms, Second Primary 1Metabolic Syndrome 1Inflammation 1Hematopoietic and Lymphatic System Neoplasm 1Healthy Adult Participants 1Dyslipidemias 1Carcinoma, Non-Small-Cell Lung 1Behavior, Addictive 1

Interventions

semaglutide 1bupropion hydrochloride, naltrexone hydrochoride drug combination 1Topiramate 1Tirzepatide 1Surveys and Questionnaires 1Qsymia 1Phlebotomy 1Phentermine 1Naltrexone 1Metformin 1Magnesium 1Liraglutide 1Glucagon-Like Peptide-1 Receptor 1Diethylpropion 1Carnitine 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dyslipidemias × Bupropion × 1 year × Clear all
NCT05756764 2025-09-09

Anti-obesity Pharmacotherapy and Inflammation

Louisiana State University Health Sciences Center in New Orleans

Active not recruiting
30 enrolled
Other

Inflammation, Obesity, Metabolic Syndrome, Dyslipidemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡